---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-002980"
form_type: "8-K"
ticker: null
cik: "0001293971"
company_name: "bluebird bio, Inc."
filed_at: "2023-01-06T23:59:59+00:00"
generated_at: "2026-06-20T18:38:31.194730+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# bluebird bio sells Rare Pediatric Disease PRV to Bristol-Myers Squibb for $95M cash

## Summary
- Sold PRV awarded for ZYNTEGLO (betibeglogene autotemcel) for β-thalassemia to Bristol-Myers Squibb.
- Total purchase price of $95 million paid in cash at closing on January 5, 2023.
- Sale closed simultaneously with execution of Asset Purchase Agreement; no assumed liabilities.
- Proceeds provide capital infusion; no specific use of proceeds disclosed.
- PRV transfer required FDA notification within 14-30 days post-closing.

## SEC filing metadata
- accession: 0001193125-23-002980
- form_type: 8-K
- cik: 0001293971
- company_name: bluebird bio, Inc.
- filed_at: 2023-01-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1293971/000119312523002980/0001193125-23-002980-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1293971/000119312523002980/d435443d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-002980
- JSON: https://secwatch.observer/filing/0001193125-23-002980.json
- Plain text: https://secwatch.observer/filing/0001193125-23-002980.txt

## Key facts
- M&A Transactions
  bluebird bio, Inc. completed a disposition involving Bristol-Myers Squibb Company for $95 million (closed 2023-01-05).
  - Action: disposition
  - Counterparty: Bristol-Myers Squibb Company
  - Consideration: $95 million
  - Closing: 2023-01-05
  source text: Pursuant to the PRV Transfer Agreement, Buyer agreed to pay the Company $95 million, payable in cash, upon the closing of the sale, which occurred simultaneously with the parties entering into the PRV Transfer Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1293971/000119312523002980/0001193125-23-002980-index.htm
- Material Agreements
  bluebird bio, Inc. entered into PRV Transfer Agreement with Bristol-Myers Squibb Company valued at $95 million (effective 2023-01-05).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Bristol-Myers Squibb Company
  - Value: $95 million
  - Effective: 2023-01-05
  source text: On January 5, 2023, bluebird bio, Inc. (the “Company”) entered into an asset purchase agreement (the “PRV Transfer Agreement”) with Bristol-Myers Squibb Company (“Buyer”), pursuant to which the Company agreed to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”) to Buyer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1293971/000119312523002980/0001193125-23-002980-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.